Orchestrating networks in the biopharmaceutical industry: small hub firms can do it

Valérie Sabatier 1, 2, 3 Vincent Mangematin 3 Tristan Rouselle 4
1 GAEL - Laboratoire d'Economie Appliquée de Grenoble
2 3PX Therapeutics
3 MTS - Management Technologique et Strategique
4 3PX Therapeutics
Abstract : The biopharmaceutical industry has been one of the most dynamic and promising sectors. The entry of Biotechnology start-ups in the 1980s led to the reconfiguration of the drug development value chain and the emergence of new competences. As the sector evolved, specialised firms appeared. As the industry matures, the production process becomes more specialised to support optimisation of technological steps. Our case studies reveal that the coordination of networks can be specialised, with the emergence of Dedicated Coordinating Firms. On the basis of four case studies of European biotechnology companies within a business model approach, this article helps understanding how coordinating a network can be successful and how small hub firms can do it.
Keywords : hub firm network business model biotechnology value chain
Document type :
Journal articles
Complete list of metadatas
http://hal.grenoble-em.com/hal-00468340
Contributor : Magali Michel <>
Submitted on : Tuesday, March 30, 2010 - 3:21:19 PM
Last modification on : Wednesday, September 11, 2019 - 4:49:17 PM

Identifiers

Collections

INRA | GRENOBLE-EM | MTI | UGA

Citation

Valérie Sabatier, Vincent Mangematin, Tristan Rouselle. Orchestrating networks in the biopharmaceutical industry: small hub firms can do it. Production Planning and Control, Taylor & Francis, 2010, 21, pp.218-228. ⟨10.1080/09537280903441971⟩. ⟨hal-00468340⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

462

Contact

Informations

CCSD